The 340B drug savings program must be reformed, Health and Human Services Secretary Alex Azar said today at a 340B conference in Washington, D.C. Azar spoke about the need for “greater transparency surrounding how these [340B] discounts are being used” and “reforms to reduce the gap between discounted prices and the reimbursement provided.” In addition, Azar said change is coming for the larger issue of prescription drug pricing, “whether it’s painful or not for pharmaceutical companies.” He spoke about the administration’s request for information , which was released in May, on ways to lower drug prices and reduce out-of-pocket costs for consumers. “Something must be done about these skyrocketing list prices, and yet the system that has been built makes that nearly impossible,” he said. “Everyone in the system, from drug companies to pharmacy benefit managers to drug wholesalers makes their money as a share of list prices.”

Related News Articles

Headline
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported…
Headline
The Senate Finance Committee held on Tuesday the third in a series of hearings on drug pricing in America, which focused on the role of pharmacy benefit…
Headline
The House Energy and Commerce Subcommittee on Oversight and Investigations today held the
Headline
A Department of Health and Human Services’ Office of Inspector General proposal to change drug discount safe harbors under the federal anti-kickback statute…
Headline
The House Committee on Energy and Commerce yesterday passed a number of AHA-supported bills that would lower prescription drug costs and strengthen the…
Headline
The AHA expressed support for a number of bills being considered today by the House Committee on Energy and Commerce that would lower prescription drug costs…